Key Takeaways SLP's Q3 EPS rose 67% to $0.45 on 10% revenue growth, beating estimates on Pro-ficiency strength. Organic sales fell 4% as biosimulation softness and cautious client spending pressured growth. SLP slashed its 2025 revenue forecast by 15% due to delays, cancellations and weaker services.Simulations Plus, Inc. ((SLP) reported third-quarter fiscal 2025 adjusted earnings of 45 cents per share, which expanded 66.7% year over year. The figure also surpassed the Zacks Consensus Estimate of 26 cents ...

Financial Performance - The company's Q3 2025 revenue reached $20.4 million, a 10% increase compared to $18.5 million in Q3 2024[4] - Adjusted EBITDA margin for Q3 2025 was 37%, up from 30% in Q3 2024[4] - Diluted EPS for Q3 2025 was $(3.35), while adjusted diluted EPS was $0.45[4] - Trailing Twelve Months (TTM) revenue for Q3 2025 was $80.4 million, a 20% increase from $67.0 million in Q3 2024[5] - The company is guiding for total revenue between $76 million and $80 million for fiscal year 2025, representing a growth of 9% to 14%[38] Software Segment - Overall software revenue grew by 6% in Q3 2025 and 16% for TTM[7] - Pro-ficiencyTM software revenue contribution was below expectations[7] - TTM revenue for Pro-ficiencyTM was $4.4 million[7] Services Segment - Overall services revenue grew by 17% in Q3 2025 and 27% for TTM[10] - Total backlog for services was $20.7 million, with over 91% expected to be converted to revenue within 12 months[10] - TTM revenue for Med Comm services was $7.3 million[10]